The increase in Neuropathic Ocular Pain Market Size is a direct consequence of increasing population of Neuropathic Ocular Pain patients in the 7MM

As per DelveInsight, the Neuropathic Ocular Pain Market is anticipated to grow in the coming years owing to the rise in the number of prevalent cases in the 7MM, the improvement in the research and development activities, and the launch of novel therapies in the Neuropathic Ocular Pain market. There are several key players involved in developing therapies for Neuropathic Ocular Pain, like Novartis, and others.

The Neuropathic Ocular Pain market report provides current treatment practices, emerging drugs, Neuropathic Ocular Pain market share of the individual therapies, current and forecasted Neuropathic Ocular Pain market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Neuropathic Ocular Pain treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Key takeaways from the Neuropathic Ocular Pain Market Research Report
• In 2020, the total cases of Neuropathic Ocular Pain (NOP) were 2,904,412 cases in the 7MM, which might increase by 2030.
• In 2020 the US accounted for 664,826 NOP cases, which is anticipated to increase by 2030.
• In 2020, the EU5 countries accounted for 1,549,516 cases, which is seen to increase by 2030.
• Among EU5 countries, Italy had the highest number of cases of Neuropathic Ocular Pain (NOP), which were 522,268 cases in 2020. As per DelveInsight's estimates, this count will increase through the study period.
• Japan, in 2020, accounted for 690,070 cases of NOP, which will decrease by the year 2030.
• The leading Neuropathic Ocular Pain Companies includes Novartis, and others.
• Promising Neuropathic Ocular Pain Pipeline Therapies includes SAF312, and others.

To discover which therapies are expected to grab the major Neuropathic Ocular Pain Market share, click here for Neuropathic Ocular Pain Market Research Report @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Neuropathic Ocular Pain Overview
Neuropathic ocular pain (NOP), also referred to as corneal neuropathic pain, is a condition in which corneal pain is seen in response to normally non-painful stimuli. This pain results from repeated direct damage to corneal nerves. Aberrant regeneration with upregulation of nociceptors responsible for the processing of painful stimuli leads to hyper-responsivity and increased perception of pain in response to even normally unpainful stimuli. The distorted neuronal excitability which persists even after the tissue has healed is the basis of symptoms of self-sustained chronic corneal pain persisting even in the absence of stimuli and clinical signs - the so-called corneal "pain without stain" or "phantom cornea." This condition is the ocular analog of systemic neuropathic pain, complex regional pain syndrome, or reflex sympathetic dystrophy (RSD).

Neuropathic Ocular Pain Epidemiology Segmentation in the 7MM
• Total Neuropathic Ocular Pain Cases of Several Eye Disorders and Surgeries
• Total Neuropathic Ocular Pain Cases

Download the report to understand which factors are driving Neuropathic Ocular Pain epidemiology trends, click here for Neuropathic Ocular Pain epidemiology segmentation @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Neuropathic Ocular Pain Treatment Market
Devising management strategies for Neuropathic Corneal Pain (NCP) patients requires differentiation of peripheral, mixed, and centralized sources of pain. Therapies for NCP can be derived from therapeutic approaches for systemic neuropathic pain and ocular post-herpetic neuralgia. Medical records reviews by experts suggest that there are nearly 100 new NCP patients treated every year. Peripheral sensitization in NCP is initiated by corneal nerve injury and subsequent inflammation. Recently, therapeutic strategies targeting neuronal regeneration have been shown to alleviate patient symptoms with autologous serum tears (AST). The rationale for this approach was based on previous reports from preclinical non-ocular neuropathic pain models on the use of neurotrophic factors, in particular, nerve growth factor (NGF). NGF reduced allodynia and hyperalgesia through reduction of reactive astrocytosis and glial modulation.

Neuropathic Ocular Pain Market Outlook
Ocular neuropathic pain, also referred to as corneal neuropathic pain, is a condition where corneal pain is seen in response to normally non-painful stimuli. This results from repeated direct damage to corneal nerves. Aberrant regeneration with upregulation of nociceptors responsible for the processing of painful stimuli leads to hyper-responsivity and increased perception of pain in response to even normally unpainful stimuli. Severe pain sensation and light sensitivity prevent those afflicted with ocular neuropathic pain from performing daily living activities and are associated with symptoms of anxiety and depression. Treatment strategies encompass several approaches.

Recommended first-line topical treatments include neuro-regenerative and anti-inflammatory agents, whilst first-line systemic pharmacotherapy includes tricyclic antidepressants and anticonvulsant. Second-line oral treatments recommended include the opioid-antagonist and analgesics. Complementary and alternative treatments, such as cardio exercise, acupuncture, omega-3 fatty acid, and gluten-free diet, may have additional benefits, as do potential non-invasive and invasive procedures in recalcitrant cases.

To learn more about the Neuropathic Ocular Pain FDA-approved drugs, click here for Neuropathic Ocular Pain Emerging Drugs & Companies and Neuropathic Ocular Pain Treatment Market @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Neuropathic Ocular Pain Market Report
• Coverage- 7MM
• Neuropathic Ocular Pain Companies- Novartis, and others.
• Neuropathic Ocular Pain Pipeline Therapies- SAF312, and others.
• Neuropathic Ocular Pain Market Dynamics: Neuropathic Ocular Pain Market Drivers and Barriers

To discover more about Neuropathic Ocular Pain Market Drugs in development, click here for Neuropathic Ocular Pain Market Dynamics and Neuropathic Ocular Pain Market Drivers & Barriers @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Neuropathic Ocular Pain (NOP)
3. Competitive Intelligence Analysis for Neuropathic Ocular Pain (NOP)
4. Neuropathic Ocular Pain (NOP): Market Overview at a Glance
5. Neuropathic Ocular Pain (NOP): Disease Background and Overview
6. Patient Journey
7. Neuropathic Ocular Pain (NOP) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Neuropathic Ocular Pain (NOP) Unmet Needs
10. Key Endpoints of Neuropathic Ocular Pain (NOP) Treatment
11. Neuropathic Ocular Pain (NOP) Marketed Products
12. Neuropathic Ocular Pain (NOP) Emerging Therapies
13. Neuropathic Ocular Pain (NOP): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Neuropathic Ocular Pain (NOP)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

To read more about the Neuropathic Ocular Pain Patient Population of the report, click here for Neuropathic Ocular Pain Unmet Needs and Patient Journey @ https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

This release was published on openPR.